Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | CFB | P00751 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753312 | 0.84 | SIGMAR1 (0.55) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL13700903 | 0.81 | CRHBP (1.00) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL30294879 | 0.81 | CRHBP (1.00) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL807228 | 0.80 | MEN1 (0.77) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL31090415 | 0.80 | CRHBP (0.66) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL18717316 | 0.79 | CRHBP (0.54) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL18955751 | 0.79 | MAPT (1.00) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL29432837 | 0.79 | MAPT (1.00) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL6797257 | 0.78 | KMT2A (0.79) | CRHBPCRHR2KDM4EMAPTALDH1A1 | |
| SCHEMBL806920 | 0.77 | CFB (0.53) | CRHBPCRHR2KDM4EALDH1A1CFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | CTNNB1, CTNNBL1, WNT3A | CRHBP 1290/4885CRHR2 3935/4885KDM4E 2497/4885 |
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | CTNNB1, CTNNBL1, WNT3A | CRHBP 1295/4885CRHR2 3916/4885KDM4E 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.